CHF Solutions (NASDAQ:CHFS) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of CHF Solutions (NASDAQ:CHFS) from a hold rating to a buy rating in a research report released on Tuesday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered shares of CHF Solutions from a hold rating to a sell rating in a research report on Tuesday, November 12th.

Shares of CHFS stock opened at $0.93 on Tuesday. The stock has a market cap of $3.09 million, a P/E ratio of -0.02 and a beta of 2.25. CHF Solutions has a one year low of $0.60 and a one year high of $13.90. The stock has a fifty day moving average price of $0.96 and a 200 day moving average price of $2.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.06 and a quick ratio of 1.51.

CHF Solutions (NASDAQ:CHFS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.41) by ($0.29). CHF Solutions had a negative net margin of 317.60% and a negative return on equity of 229.50%. The business had revenue of $1.25 million during the quarter. Equities research analysts anticipate that CHF Solutions will post -6.45 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC bought a new stake in shares of CHF Solutions in the 2nd quarter valued at approximately $34,000. Anson Funds Management LP bought a new position in shares of CHF Solutions during the 2nd quarter worth approximately $278,000. Finally, Virtu Financial LLC bought a new position in shares of CHF Solutions during the 3rd quarter worth approximately $48,000. 8.49% of the stock is currently owned by institutional investors.

CHF Solutions Company Profile

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

See Also: Market Capitalization

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.